当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2017年第12期
编号:13056767
小细胞肺癌预后因子的研究进展(5)
http://www.100md.com 2017年4月25日 中国医药导报 2017年第12期
     [35] Olsen IH,Langer SW,Jepsen I,et al. First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carbonplation,etoposide,and vincristine:a single institution experience [J]. Acta Oncol,2012,51(1):97-100.

    [36] Miko E,Margitai Z,Czimmerer Z,et al. miR- 126 inhibits proliferation of small cell lung cancer cells by targeting SLC7A5 [J]. FEBS Lett,2011,585(8):1191-1196.

    [37] Mancuso G,Bovio E,Rena O,et al. Prognostic impact of a 3-MicroRNA signature in cytological samples of small cell lung cancer [J]. Cancer Cytopathol,2016,124(9):621-629.

    [38] Zhou R, Zhon XS, Yin ZY, et al. Tumor invasion and metastasis regulated by microRNA-184 and microRNA-574-5p in small-cell lung cancer [J]. Oncotarget,2015, 6(42):44609-44622.

    [39] Hong B,Zu Y. Detecting circulating tumor cells:current challenges and new trends [J]. Theranostics,2013,3(6): 377-394.

    [40] 溫坚,何志江,刘云军,等.小细胞肺癌患者外周血循环肿瘤细胞检测的临床意义[J].黑龙江医学,2016,40(2):151-153.

    [41] Hou JM,Greystoke A,Lancashire L,et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients under-go?鄄ing chemotherapy [J]. Am J Pathol,2009,175(2):808-816.

    (收稿日期:2016-11-28 本文编辑:李岳泽), 百拇医药(王洪玲 李琳 王键玮 喻昌利)
上一页1 2 3 4 5